NCT00585845View on ClinicalTrials.gov

Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Malignant Epithelial MesotheliomaAdenocarcinoma of the PancreasCarcinoma, Non-Small-Cell LungAdenocarcinoma of the Ovaries
Interventions
BIOLOGICAL

CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin

2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10\^8 cfu to 1x10\^10 cfu.

Trial Locations (4)

19104

University of Pennsylvania Abramson Family Cancer Research Center, Philadelphia

20892

National Cancer Institute, NCI, Bethesda

21231

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore

91120

Hadassah Hebrew University Medical Center, Jerusalem

Sponsors
All Listed Sponsors
lead

Anza Therapeutics, Inc.

INDUSTRY

NCT00585845 - Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment | Biotech Hunter | Biotech Hunter